2023
January
23,
2023
|
08:29 AM
Europe/Amsterdam
Ultravist™-300, -370 receives green light for indication extension for use in contrast-enhanced mammography (CEM) in a European Workshare Procedure / CEM is emerging modality combining digital mammography with the administration of a contrast agent ...
Read more
2022
October
25,
2022
|
08:28 AM
Europe/Amsterdam
The REALISE study explored symptom burden and impact of menopause symptoms in women across multiple countries, and the views of their treating physicians. / This study confirmed vasomotor symptoms (VMS) are considered the most common and distressing...
Read more
October
20,
2022
|
08:29 AM
Europe/Amsterdam
Bayer, together with the Bill & Melinda Gates Foundation, are jointly funding pre-clinical research in the area of novel non-hormonal contraception / This collaboration with the Bill & Melinda Gates Foundation will contribute to expanding access to c...
Read more
October
17,
2022
|
09:00 AM
Europe/Amsterdam
Study plans to investigate elinzanetant as non-hormonal treatment for vasomotor symptoms caused by endocrine therapy in breast cancer patients / Elinzanetant is an innovative non-hormonal development compound in development for the treatment of vaso...
Read more
October
14,
2022
|
09:30 AM
Europe/Amsterdam
Mirena® (52mg LNG IUS), Bayer’s long-acting reversible intrauterine system, received regulatory approval in the European Workshare Procedure for up to eight years in contraception, now offering the longest contraceptive duration of use for any hormon...
Read more
August
18,
2022
|
14:30 PM
Europe/Amsterdam
Mirena®, Bayer’s long-acting reversible intrauterine system, now approved by U.S. FDA for up to eight years in contraception / Mirena (52mg LNG IUS) now offers the longest contraceptive duration of use for any hormonal intrauterine system / The IUS i...
Read more
2021
October
05,
2021
|
08:30 AM
Europe/Amsterdam
Supports Bayer’s global sustainability commitment of providing 100 million women in low- and middle-income countries (LMICs) with access to modern contraception by 2030 / Investment in new production capabilities in Alajuela, Costa Rica and Turku, Fi...
Read more
September
26,
2021
|
08:00 AM
Europe/Amsterdam
The ‘Your Right to Plan’ campaign aims at improving family planning and reproductive health services to Egypt’s underserved communities / The five-year partnership involves a total donation of EUR 330,000 / The program provides access to medical serv...
Read more
August
31,
2021
|
14:30 PM
Europe/Amsterdam
Elinzanetant is an innovative non-hormonal development compound investigated for the treatment of vasomotor symptoms during menopause...
Read more
2020
November
18,
2020
|
08:30 AM
Europe/Amsterdam
Focus on fostering development of integrated healthcare solutions in fields of cardiometabolic and renal diseases, oncology, and women’s health / Germany’s Federal Minister of Health Jens Spahn to give keynote at the virtual digital health forum "G4A...
Read more
September
09,
2020
|
08:30 AM
Europe/Amsterdam
Berlin, Germany, September 9, 2020 - Bayer, a global leader in women’s healthcare, today announced that, further to its press release of August 11, 2020, it has now completed the acquisition of UK-based biotech company KaNDy Therapeutics Ltd. to expa...
Read more
August
20,
2020
|
19:00 PM
Europe/Amsterdam
Leverkusen, August 20, 2020 - Bayer announced today that it has reached agreements with plaintiff law firms to resolve approximately 90% of the nearly 39,000 total filed and unfiled U.S. Essure™ claims involving women who allege device-related injuri...
Read more
August
11,
2020
|
08:30 AM
Europe/Amsterdam
Further expansion of Bayer’s drug development pipeline in Women’s Healthcare / Innovative non-hormonal oral compound NT-814 to alleviate menopausal symptoms / Development compound recently completed Phase IIb / Reinforces Bayer’s position in Women’s ...
Read more
January
13,
2020
|
13:00 PM
Europe/Amsterdam
Underlining Bayer’s commitment in the field of women’s health / Potential commercial milestone payments of up to USD 310 million and tiered royalties on net sales in the double-digit range...
Read more
2018
December
20,
2018
|
09:00 AM
Europe/Amsterdam
Berlin, December 20, 2018 - Bayer announced today that Visanne™ has been approved by the Chinese regulatory authorities for the treatment of endometriosis. Visanne is a once-daily oral tablet containing dienogest 2 mg that has been developed specific...
Read more
2017
July
03,
2017
|
08:30 AM
Europe/Amsterdam
Berlin, July 3, 2017 - Bayer announced today that the first patient was enrolled in a Phase III clinical study program ASTEROID which will investigate vilaprisan in women suffering from uterine fibroids. Vilaprisan, discovered at Bayer, is a novel or...
Read more
